<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01963299</url>
  </required_header>
  <id_info>
    <org_study_id>GIRARD-BERTRAND 2013</org_study_id>
    <nct_id>NCT01963299</nct_id>
  </id_info>
  <brief_title>Clonidine - Ropivacaine in Peribulbar Anesthesia</brief_title>
  <acronym>CRAPO</acronym>
  <official_title>Prospective Randomised Double-blind Study to Compare Ropivacaine 10mg/mL Alone Versus Ropivacaine 10mg/mL Associated With Clonidine 1µg/kg for Peribulbar Anesthesia in Posterior Eye Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study conducted in 60 patients, randomly assigned to one of two groups of 30: the&#xD;
      first will receive ropivacaine alone and the second will receive the association&#xD;
      ropivacaine/clonidine.&#xD;
&#xD;
      The aim of the study is to prove that the association of Clonidine with Ropivacaine is more&#xD;
      effective than ropivacaine alone for locoregional anaesthesia of the eye for retinal surgery.&#xD;
&#xD;
      The principal interest of this association of drugs is that it procures faster and longer&#xD;
      anaesthesia of the eye with less ropivacaine (therefore fewer injections). This provides&#xD;
      greater comfort to the patient during and after the intervention.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 16, 2013</start_date>
  <completion_date type="Actual">October 7, 2013</completion_date>
  <primary_completion_date type="Actual">October 7, 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose of ropivacaine injected 10 mg/ml: necessary to obtain complete ocular akinesia</measure>
    <time_frame>up to 1 hour</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to achieve akinesia</measure>
    <time_frame>up to 1 hour</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Indication for Surgery of the Posterior Segment Under Locoregional Anaesthesia</condition>
  <arm_group>
    <arm_group_label>Ropivacaine alone group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ropivacaine/Clonidine group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5 ml Ropivacaine 10% + physiological saline</intervention_name>
    <arm_group_label>Ropivacaine alone group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5 ml Ropivacaine 10% + Clonidine 1 µg/kg</intervention_name>
    <arm_group_label>Ropivacaine/Clonidine group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients who have given written informed consent&#xD;
&#xD;
          -  any adult patient about to undergo their first operation involving the posterior&#xD;
             segment of the eye under peribulbar anaesthesia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  persons without National Health Insurance&#xD;
&#xD;
          -  pregnant or breast-feeding women, patients &lt; 18, patients who cannot give their&#xD;
             consent, patient's refusal of Loco-Regional Anesthesia, patients who cannot remain in&#xD;
             dorsal decubitus dorsal for at least 1h&#xD;
&#xD;
          -  contra-indication for Loco-Regional Anesthesia&#xD;
&#xD;
          -  hypersensitivity to the study drugs (ropivacaine, clonidine), to the corresponding&#xD;
             excipients or hypersensitivity to local anaesthetics other than amide-type&#xD;
             ropivacaine.&#xD;
&#xD;
          -  disorders of periorbital or oculomotor sensitivity, patients with glaucoma, patients&#xD;
             with chronic pain and on morphines&#xD;
&#xD;
          -  uncontrolled arterial hypertension, clonidine per os at home, arterial hypotension&#xD;
             before the intervention (SAP &lt; 90 mmHg)&#xD;
&#xD;
          -  Surgery for diabetic retinopathy, patients with unbalanced diabetes, eye with prior&#xD;
             posterior segment surgery&#xD;
&#xD;
          -  Contra-indications mentioned on the summary of product characteristics for clonidine&#xD;
             (known hypersensitivity to the active ingredients or one of its excipients, Heart rate&#xD;
             below 60bpm, severe Bradycardia due to sinoatrial node disease or second or third&#xD;
             degree atrioventricular block, Depression, Sultopride).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>October 10, 2013</study_first_submitted>
  <study_first_submitted_qc>October 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2013</study_first_posted>
  <last_update_submitted>January 9, 2019</last_update_submitted>
  <last_update_submitted_qc>January 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clonidine</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

